← Back to screener

Vir Biotechnology, Inc. VIR

Rank #2017 · Nasdaq · $1.9B market cap
Audited by Ernst & Young LLP, no going-concern flag in the latest filing.
Score
36.2
P/E
-3.1
P/B
0.92
ROE
-29.6%
Op. Margin
-794.0%
Debt Ratio
12%

Health Check — percentile rank within this universe, based on the latest annual filing

Valuation ★★☆☆☆
Average

P/E -3.1x, P/B 0.92x. Ranks in the top 53% of the universe.

Profitability ★☆☆☆☆
Poor

ROE -29.6%. Ranks in the top 90% of the universe.

Safety ★★★★☆
Excellent

Debt ratio 12%. Ranks in the top 10% of the universe. Under 100% is generally considered a safe level.

Growth ★☆☆☆☆
Poor

Revenue decline of 94.7% year over year. Ranks in the top 99% of the universe.

Safety is the relative strength · Profitability is the relative weakness (relative to this universe).

Financials annual, from SEC 10-K filings

FYRevenueOp. IncomeNet IncomeEquityOp. Margin%Debt%
2019$0.0B$-0.1B$-0.1B$-0.0B-3009.5-773
2020$0.0B$-0.1B$-0.1B$-0.1B-1112.6-128
2021$0.0B$-0.2B$-0.2B$-0.2B-2199.7-113
2022$0.1B$-0.3B$-0.3B$0.4B-388.9123
2023$1.1B$0.4B$0.5B$0.7B38.4101
2024$1.6B$0.8B$0.5B$1.4B51.623
2025$0.1B$-0.7B$-0.6B$2.1B-794.012

← See the full screener